Xenon Pharmaceuticals (NASDAQ: XENE)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.410 | -0.350 | 0.0600 | ||||
REV | 8.700M | 8.766M | 66.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Xenon Pharmaceuticals (NASDAQ: XENE) through any online brokerage.
There are no as such competitors for Xenon Pharmaceuticals.
The latest price target for Xenon Pharmaceuticals (NASDAQ: XENE) was reported by RBC Capital on Wednesday, May 11, 2022. The analyst firm set a price target for 41.00 expecting XENE to rise to within 12 months (a possible 32.82% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Xenon Pharmaceuticals (NASDAQ: XENE) is $30.87 last updated May 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for Xenon Pharmaceuticals.
Xenon Pharmaceuticals’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Xenon Pharmaceuticals.
Xenon Pharmaceuticals is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.